Omics-Based Clinical Trials Market Research Reveals Path To $47.77 Billion By 2030

The rapid advancements in biotechnology and data analytics are paving the way for remarkable growth in the omics-based clinical trials sector. As precision medicine gains traction and technology evolves, this market is set to experience significant expansion and innovation over the coming years. Below is an in-depth look at the market size, key players, emerging trends, and critical segments driving this dynamic field.

Growth Prospects and Market Size of the Omics-Based Clinical Trials Industry
The omics-based clinical trials market is projected to expand considerably, reaching a valuation of $47.78 billion by 2030. This represents a strong compound annual growth rate (CAGR) of 8.5% during the forecast period. The surge can be linked to several factors, including the widespread adoption of precision medicine methodologies, increased investments in data-driven clinical trial platforms, growth in AI-powered patient recruitment systems, broader regulatory acceptance of omics-based endpoints, and heightened demand for more efficient clinical outcomes. Anticipated trends influencing this market include the growing use of biomarker-driven trial designs, multi-omics patient stratification approaches, integration of real-world evidence analytics, expansion in precision oncology trials, and a stronger emphasis on optimizing trials through data-centric strategies.

The omics-based clinical trials market size has grown strongly in recent years. It will grow from $31.71 billion in 2025 to $34.49 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing complexity of clinical trial designs, growth in genomic and proteomic research, rising demand for personalized therapies, expansion of clinical research infrastructure, increasing collaboration between pharma and academic institutions.

Download a free sample of the omics-based clinical trials market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Factors Propelling Growth in the Omics-Based Clinical Trials Market
One of the primary drivers behind the market's expansion is the rising popularity of precision medicine, which relies heavily on omics data to tailor treatments to individual patients. This personalized approach is revolutionizing clinical trials by improving the accuracy and effectiveness of therapies. Additionally, increased funding and investments from both public and private sectors are fueling development in data analytics technologies that support these trials.

Another important factor is the growing acceptance by regulatory authorities of omics-based endpoints as valid measures of treatment efficacy. This shift is encouraging pharmaceutical companies and research organizations to incorporate omics technologies more widely, enhancing trial design and outcome predictability. Moreover, the adoption of AI-enabled tools for patient recruitment and data processing is streamlining trial workflows and boosting operational efficiency.

View the full omics-based clinical trials market report:
https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Organizations Influencing the Omics-Based Clinical Trials Landscape
Several prominent companies are at the forefront of the omics-based clinical trials market, including Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.

Significant Acquisition Enhances Market Capabilities
In June 2025, Bruker Corporation, a US-based producer of scientific instruments and diagnostic tests, acquired Biocrates Life Sciences AG, a biotechnology firm based in Austria, for an undisclosed sum. This acquisition aims to bolster Bruker's multiomics offerings by integrating Biocrates' advanced mass spectrometry-based metabolomics technologies. The goal is to provide standardized, reproducible, and comprehensive workflows tailored for life sciences and clinical research, thereby strengthening Bruker's position in the omics-based clinical trial space.

Current Innovation Trends in Omics-Based Clinical Trials
Companies in this market are aggressively pursuing next-generation technologies like HiFi sequencing to improve the precision, speed, and scope of multi-omics data analysis. HiFi sequencing, a cutting-edge next-generation sequencing technology, uses circular consensus sequencing (CCS) to produce long, highly accurate DNA reads. This enables researchers to conduct thorough analysis of genomes, transcriptomes, and epigenomes, which can significantly enhance trial accuracy and patient stratification.

For example, in October 2024, Pacific Biosciences of California Inc., collaborating with Singapore's Agency for Science, Technology and Research (A*STAR) and South Korea's Macrogen Inc., opened a state-of-the-art genomics lab in Singapore. Equipped with advanced long-read sequencing technology, the facility supports applications spanning whole genome sequencing, transcriptomics, epigenetics, and metagenomics. It also fosters partnerships among global scientists and local institutions to accelerate progress in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, the lab offers training programs and shared access to high-throughput sequencing infrastructure, boosting innovation capacity across the Asia-Pacific region.

Primary Segments Driving Growth in the Omics-Based Clinical Trials Market
This market is divided into distinct segments based on type, phase, study design, application, and end-user to better understand evolving trends and demands.

By Type, the market covers:
- Genomics
- Proteomics
- Metabolomics
- Transcriptomics

By Phase, clinical trials are segmented into:
- Phase I
- Phase II
- Phase III
- Phase IV

Study designs are classified as:
- Interventional Studies
- Observational Studies
- Expanded Access Studies

Applications include:
- Oncology
- Cardiovascular diseases
- Neurology
- Infectious diseases
- Metabolic disorders

End-users span:
- Pharmaceutical and biotechnology companies
- Academic and research institutes
- Contract research organizations (CROs)
- Hospitals and diagnostic laboratories

Further detailed subcategories include Genomics subdivisions such as Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Gene Sequencing; Proteomics areas like Protein Expression Profiling, Post-Translational Modifications Analysis, and Protein-Protein Interaction Mapping; Metabolomics branches including Targeted and Untargeted Metabolomics along with Metabolic Flux Analysis; and Transcriptomics segments covering Microarray Analysis, Single-Cell Transcriptomics, and Gene Expression Profiling.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.